GELS vs WST vs STE Stock Comparison

Gelteq, West Pharmaceutical Services and Steris Prices as of Nov 16, 2026 Peers: Industry group
GELS Gelteq Ltd
$0.36 -20.0% 1M -63.9% 1Y
Market cap
$2.43M
P/E
–
Revenue (TTM)
—
Div. yield
–
Contract Manufacturing Healthcare
STE STERIS plc
$261.89 +17.6% 1M +1.3% 1Y
Market cap
$25.07B
P/E
30.3x
Revenue (TTM)
$6.17B
Div. yield
0.01%
Medical Devices Healthcare
6 wins

Head to Head

12 decided of 12

West Pharmaceutical Services leads on 6 of the 12 questions below (West Pharmaceutical Services 6, Steris 6). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionGELSWSTSTELeader
Larger companyMarket capitalisation $2.43M $29.07B $25.07B WST
Cheaper on earningsLower P/E, profitable companies only — 45.5x 30.3x STE
Cheaper on forward earningsLower price / next fiscal year consensus EPS — 41.3x 22.4x STE
Faster revenue growthRevenue growth, trailing twelve months — +12.6% +8.1% WST
More profitableNet margin, trailing twelve months — 18.8% 13.4% WST
Better return on capitalReturn on invested capital — 19.3% 9.5% WST
Less leveragedLower net debt / EBITDA — -0.3x 0.8x WST
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.01% STE
Better 1-year returnPrice return, last 12 months -63.9% +60.0% +1.3% WST
Better 5-year returnAnnualised price return, 5 years — -1.2%/yr +2.5%/yr STE
Less volatileAnnualised volatility, 1 year 160.3% 31.2% 26.9% STE
Higher overall scoreMean of the five percentile scores vs peers — 69/100 70/100 STE

Percentile Scorecard

GELSWSTSTE

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisGELSWSTSTE
Valuation – 49 #124 of 243 73 #67 of 243
Growth – 49 #118 of 228 51 #113 of 228
Profitability – 95 #13 of 222 90 #23 of 222
Financial Health 58 #6 of 13 77 #58 of 248 64 #90 of 248
Shareholder Returns – 76 #39 of 159 75 #41 of 159
Overall – 69 70
  • GELS ranked among 13 companies in Pharma Services
  • WST ranked among 252 companies in Medical Devices and Diagnostics
  • STE ranked among 252 companies in Medical Devices and Diagnostics

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodGELSWSTSTESPY
1 month -20.0%+8.9%+17.6% -3.0%
3 months -35.7%+20.7%+14.0% -4.2%
6 months -11.1%+37.3%+23.0% +0.2%
Year to date -55.0%+52.0%+3.3% +8.5%
1 year -63.9%+60.0%+1.3% +10.1%
3 years —+22.0%+30.8% +64.1%
3 years, per year —+6.9%+9.4% +18.0%
5 years —-6.0%+13.1% +58.1%
5 years, per year —-1.2%+2.5% +9.6%
10 years —+425.7%+293.8% +239.6%
10 years, per year —+18.1%+14.7% +13.0%

Risk

MeasureGELSWSTSTESPY
Volatility, 1Y 160.3%31.2%26.9% 13.8%
Downside volatility, 1Y 124.2%30.8%25.5% 14.2%
Beta vs S&P 500, 1Y 1.810.630.39 1.00
Return / volatility, 1Y -0.401.920.05 0.74
Max drawdown, 5Y -92.5%-59.6%-36.5% -25.4%
From 52-week high -76.5%0.0%-2.5% -5.0%
52-week high $1.53$418.08$268.65 $779.14
52-week low $0.36$230.95$199.40 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleGELSWSTSTE
P/E now vs peer median —median 34.7x 45.9xmedian 26.5x 31.1xmedian 26.5x
P/S now vs peer median —median 2.5x 8.6xmedian 2.7x 4.2xmedian 2.7x
EV/EBITDA now vs peer median —median 29.1x 29.9xmedian 18.6x 16.2xmedian 18.6x
P/FCF now vs peer median -5.7xmedian 21.0x 64.2xmedian 25.6x 27.4xmedian 25.6x
P/B now vs peer median 0.4xmedian 1.6x 9.8xmedian 2.5x 3.5xmedian 2.5x
PEG now vs peer median —median 1.98 6.86median 0.98 2.04median 0.98

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsGELSWSTSTE
Revenue – $3.40B $6.17B
Gross profit – $1.28B $2.75B
Operating income – $780.20M $1.17B
Net income – $638.90M $829.70M
Free cash flow – $453.40M $937.20M
R&D – $75.60M $118.40M
EPS (diluted) – $9.02 $8.47
Cash & equivalents $6.26K $464.10M $531.10M
Total debt $9.08K $202.90M $1.89B
Shares (diluted) 9.27M 70.80M 97.60M
Enterprise value $283.86K $26.85B $23.19B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricGELSWSTSTE
P/E – 45.9x 31.1x
P/FCF -5.7x 64.2x 27.4x
P/Operating cash flow – 44.4x 19.9x
P/S – 8.6x 4.2x
P/B 0.4x 9.8x 3.5x
P/Tangible book -1.2x 9.8x 4.4x
EV/EBITDA – 29.9x 16.2x
EV/EBIT – 36.9x 23.1x
EV/Revenue – 8.5x 4.4x
EV/FCF – 63.6x 28.8x
EV/Operating cash flow – 44.0x 21.0x
PEG (3Y EPS CAGR) – 6.86 2.04

Growth

14 metrics
MetricGELSWSTSTE
Revenue growth (1Y) – 12.6% 8.1%
Revenue CAGR (3Y) – 5.1% 8.6%
Gross profit growth (1Y) – 18.9% 8.8%
Gross profit CAGR (3Y) – 4.7% 9.4%
Operating income growth (1Y) – 32.7% 20.2%
Operating income CAGR (3Y) – 6.6% -4.1%
Net income growth (1Y) – 29.9% 20.2%
Net income CAGR (3Y) – 4.5% 14.6%
EPS growth (1Y) – 33.2% 21.6%
EPS CAGR (3Y) – 6.7% 15.3%
Operating cash flow growth (1Y) – -5.7% -0.9%
Operating cash flow CAGR (3Y) – -5.2% 15.0%
Free cash flow growth (1Y) – 19.6% -2.5%
Free cash flow CAGR (3Y) – 2.6% 20.5%

Profitability

14 metrics
MetricGELSWSTSTE
Gross margin – 37.6% 44.6%
EBITDA margin – 28.4% 27.0%
Operating margin – 23.0% 19.0%
Pretax margin – 23.2% 18.2%
Net margin – 18.8% 13.4%
FCF margin – 13.3% 15.2%
Operating cash flow margin – 19.3% 20.9%
Return on equity – 21.4% 11.4%
Return on assets – 15.7% 7.7%
Return on invested capital – 19.3% 9.5%
Return on capital employed – 22.8% 12.3%
Asset turnover – 0.8x 0.6x
Cash conversion (OCF / net income) – 1.0x 1.6x
Stock comp / revenue – 0.8% 1.0%

Financial Health

11 metrics
MetricGELSWSTSTE
Debt / assets 0.1% 5.0% 17.7%
Debt / equity 0.0x 0.1x 0.3x
Net debt / EBITDA – -0.3x 0.8x
Debt / FCF – 0.4x 2.0x
Liabilities / assets 29.4% 26.9% 32.1%
Equity / assets 70.6% 73.1% 67.9%
Interest coverage – 96.3x 20.5x
Current ratio 0.1x 2.8x 2.1x
Quick ratio 0.1x 1.9x 1.3x
Cash ratio 0.0x 0.7x 0.4x
Altman Z-score – 19.45 5.98

Shareholder Returns

7 metrics
MetricGELSWSTSTE
Dividend yield – 0.2% 1.0%
Net buyback yield – 2.3% 1.3%
Shareholder yield – 2.5% 2.3%
Payout ratio (earnings) – 9.8% 30.4%
Payout ratio (FCF) – 13.9% 26.9%
Dividend growth (1Y) – 3.5% 9.5%
Dividend CAGR (3Y) – 3.7% 9.6%

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusGELSWSTSTE
Forward P/E – 41.3xFY2026 22.4xFY2026
EPS, next fiscal year – $10.10FY2026 $11.78FY2026
EPS growth, next FY – +38.5%FY2026 +15.8%FY2026
EPS growth, the year after – +8.3% +11.9%
Revenue, next fiscal year – $3.28BFY2026 $6.61BFY2026
Revenue growth, next FY – +6.9%FY2026 +11.3%FY2026
Revenue growth, the year after – +16.7% -0.3%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersGELSWSTSTE
Held by institutions – 99.5% 97.1%
Institutions holding – 836 831
Change in shares held, QoQ – -0.9% +1.1%
Institutions buying – 450 405
Institutions selling – 261 302
Buyers to sellers – 1.72 1.34

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

GELSWSTSTE
GELS 1.00 0.02 -0.01
WST 0.02 1.00 0.29
STE -0.01 0.29 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, GELS, WST and STE?

West Pharmaceutical Services (WST) is the largest by market capitalisation: Gelteq (GELS) $2.43M, West Pharmaceutical Services (WST) $29.07B, Steris (STE) $25.07B.

Which stock is cheaper, GELS, WST and STE?

Steris (STE) trades on the lowest price-to-earnings ratio (West Pharmaceutical Services (WST) 45.5x, Steris (STE) 30.3x). On next year's consensus earnings, Steris (STE) is cheapest (West Pharmaceutical Services (WST) 41.3x, Steris (STE) 22.4x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

West Pharmaceutical Services (WST) grew revenue fastest over the trailing twelve months: West Pharmaceutical Services (WST) +12.6%, Steris (STE) +8.1%.

Which company is more profitable?

West Pharmaceutical Services (WST) has the highest net margin (West Pharmaceutical Services (WST) 18.8%, Steris (STE) 13.4%). On return on invested capital, West Pharmaceutical Services (WST) leads (West Pharmaceutical Services (WST) 19.3%, Steris (STE) 9.5%).

Which stock has performed better?

Over the past year West Pharmaceutical Services (WST) returned the most: Gelteq (GELS) -63.9%, West Pharmaceutical Services (WST) +60.0%, Steris (STE) +1.3%. Over five years, Steris (STE) compounded fastest (West Pharmaceutical Services (WST) -1.2%/yr, Steris (STE) +2.5%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Steris (STE) has the highest dividend yield: Gelteq (GELS) 0.00%, West Pharmaceutical Services (WST) 0.00%, Steris (STE) 0.01%. Gelteq (GELS) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Steris (STE) has been the steadiest (Gelteq (GELS) 160.3%, West Pharmaceutical Services (WST) 31.2%, Steris (STE) 26.9%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, GELS, WST and STE?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, West Pharmaceutical Services (WST) leads on 6. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.